Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | RXRA | P19793 | 8/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 8/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 8/20 | 0.40 |
| ▸ | ALOX5AP | P20292 | 7/20 | 0.36 |
| ▸ | FEN1 | P39748 | 7/20 | 0.36 |
| ▸ | NCF1 | P14598 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20012069 | 0.85 | SCN9A (0.44) | SCN9ARXRAGRIN1GRIN2BALOX5AP | |
| SCHEMBL16265343 | 0.83 | SCN9A (0.45) | SCN9ARXRAGRIN1GRIN2BALOX5AP | |
| SCHEMBL17767964 | 0.81 | NUDT1 (0.44) | SCN9ARXRAGRIN1GRIN2BALOX5AP | |
| SCHEMBL16631778 | 0.81 | MCHR1 (0.47) | SCN9AALOX5APFEN1 | |
| SCHEMBL30278077 | 0.80 | SCN9A (0.42) | SCN9ARXRAGRIN1GRIN2BALOX5AP | |
| SCHEMBL17767985 | 0.79 | MCHR1 (0.46) | SCN9ARXRAGRIN1GRIN2BALOX5AP | |
| SCHEMBL14880376 | 0.78 | SCN9A (0.44) | SCN9ARXRAGRIN1GRIN2BALOX5AP | |
| SCHEMBL17778644 | 0.76 | SCN9A (0.40) | SCN9ARXRAGRIN1GRIN2BALOX5AP | |
| SCHEMBL8348332 | 0.76 | HRH1 (0.42) | HRH3 | |
| SCHEMBL12487754 | 0.75 | NOS1 (0.45) | SCN9AHRH3NCF1NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9845297-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2017-12-19 | — | — | US | disclosed |
| US-9845297-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2017-12-19 | — | — | US | disclosed |
| US-20160031828-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | SILICON VALLEY BANK | 2016-02-04 | — | — | US | disclosed |
| US-20160031828-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | SILICON VALLEY BANK | 2016-02-04 | — | — | US | disclosed |
| US-9216979-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2015-12-22 | — | — | US | disclosed |
| US-9216979-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2015-12-22 | — | — | US | disclosed |
| US-20130090326-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | RIB-X PHARMACEUTICALS, INC. (US) | 2013-04-11 | — | — | US | disclosed |
| US-20130090326-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | RIB-X PHARMACEUTICALS, INC. (US) | 2013-04-11 | — | — | US | disclosed |
| WO-2011047323-A2 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090326-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | MPO, LPO, CAT | SCN9A 4717/4885HRH3 3537/4885RXRA 2213/4885 |
| US-20160031828-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | MPO, LPO, CAT | SCN9A 4717/4885HRH3 3537/4885RXRA 2213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.